Adding trastuzumab to carboplatin and paclitaxel improves overall survival in advanced-stage HER2/NEU overexpressing uterine serous carcinoma or carcinosarcoma

被引：0
|
作者：
Lu, Ting-Fang [1 ]
Lou, Sun [1 ]
Shih, Yu-Hsiang [1 ]
Chen, Yen-Fu [1 ]
Fan, Chun Ting [1 ]
Wang, Shao-Jing [1 ]
Hsu, Shih-Tien [1 ]
Liu, Chin-Ku [1 ]
Hwang, Sheau-Feng [1 ]
Lu, Chien-Hsing [1 ]
机构：
[1] Taichung Vet Gen Hosp, Obstet & Gynecol Dept, Taichung, Taiwan
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR017
引用
收藏
页码：A45 / A46
页数：2
相关论文
共 50 条
  • [1] A retrospective study evaluating the effect of trastuzumab addition to carboplatin/paclitaxel on overall survival in patients with advanced-stage HER2/neu-overexpressing uterine serous carcinoma or carcinosarcoma
    Lu, Ting-Fang
    Sun, Lou
    Shih, Yu-Hsiang
    Chen, Yen-Fu
    Fan, Chun-Ting
    Wang, Shao-Jing
    Hsu, Shih-Tien
    Liu, Chih-Ku
    Hwang, Sheau-Feng
    Lu, Chien-Hsing
    BMC MEDICINE, 2025, 23 (01):
  • [2] Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
    Fader, Amanda N.
    Roque, Dana M.
    Siegel, Eric
    Buza, Natalia
    Hui, Pei
    Abdelghany, Osama
    Chambers, Setsuko
    Secord, Angeles Alvarez
    Havrilesky, Laura
    O'Malley, David M.
    Backes, Floor J.
    Nevadunsky, Nicole
    Edraki, Babak
    Pikaart, Dirk
    Lowery, William
    ElSahwi, Karim
    Celano, Paul
    Bellone, Stefania
    Azodi, Masoud
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Schwartz, Peter E.
    Santin, Alessandro D.
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 3928 - 3935
  • [3] Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002)
    Santin, A. D.
    Fader, A.
    Roque, D. M.
    Eric, S.
    Buza, N.
    Pei, H.
    Abdelghany, O.
    Chambers, S. K.
    Secord, A. Alvarez
    Havrilesky, L.
    O'Malley, D. M.
    Backes, F.
    Nevadunsky, N.
    Edraki, B.
    Pikaart, D.
    Lowery, W.
    ElSahwi, K.
    Celano, P.
    Bellone, S.
    Azodi, M.
    Litkouhi, B.
    Elena, R.
    Silasi, D. A.
    Schwartz, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 15 - 16
  • [4] Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002)
    Santin, A. D.
    Fader, A. N.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 12 - 12
  • [5] Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis
    Fader, A. N.
    Roque, D. M.
    Siegel, E. R.
    Buza, N.
    Hui, P.
    Havrilesky, L. J.
    Secord, A. A.
    O'Malley, D. M.
    Backes, F. J.
    Nevadunsky, N. S.
    Chambers, S. K.
    Edraki, B.
    Celano, P.
    Bellone, S.
    Azodi, M.
    Ratner, E. S.
    Litkouhi, B.
    Silasi, D. A.
    Schwartz, P. E.
    Santin, A. D.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 7 - 8
  • [6] Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
    Santin, Alessandro D.
    Bellone, Stefania
    Roman, Juan J.
    McKenney, Jesse K.
    Pecorelli, Sergio
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2008, 102 (02) : 128 - 131
  • [7] Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu
    Yadav, Ghanshyam
    Roque, Dana M.
    Bellone, Stefania
    Manavella, Diego D.
    Hartwich, Tobias M. P.
    Zipponi, Margherita
    Harold, Justin
    Tymon-Rosario, Joan
    Mutlu, Levent
    Altwerger, Gary
    Menderes, Gulden
    Ratner, Elena
    Buza, Natalia
    Hui, Pei
    Huang, Gloria S.
    Andikyan, Vaagn
    Clark, Mitchell
    Azodi, Masoud
    Schwartz, Peter E.
    Alexandrov, Ludmil B.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2022, 166 (02) : 351 - 357
  • [8] Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
    P Todeschini
    E Cocco
    S Bellone
    J Varughese
    K Lin
    L Carrara
    F Guzzo
    N Buza
    P Hui
    D-A Silasi
    E Ratner
    M Azodi
    P E Schwartz
    T J Rutherford
    S Pecorelli
    A D Santin
    British Journal of Cancer, 2011, 105 : 1176 - 1182
  • [9] Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
    Todeschini, P.
    Cocco, E.
    Bellone, S.
    Varughese, J.
    Lin, K.
    Carrara, L.
    Guzzo, F.
    Buza, N.
    Hui, P.
    Silasi, D-A
    Ratner, E.
    Azodi, M.
    Schwartz, P. E.
    Rutherford, T. J.
    Pecorelli, S.
    Santin, A. D.
    BRITISH JOURNAL OF CANCER, 2011, 105 (08) : 1176 - 1182
  • [10] HER2/neu Overexpression and Recurrence Risk in Early Stage Uterine Serous Carcinoma
    Blakaj, A.
    Jairam, V.
    Buza, N.
    Schwartz, P.
    Santin, A.
    Damast, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S218 - S219
12345